Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men
| Autor: | Ping-Yiu Yik, Bernard M.Y. Cheung, Wilson J. C. Tsui, You-Qiang Song, Sidney Tam, Leung-Wing Chu, John E. Morley, Rachel L.C. Wong, Peter W. H. Lee, Karen S.L. Lam |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty Cross-sectional study Endocrinology Diabetes and Metabolism Biological Availability Lower risk behavioral disciplines and activities Cognition Endocrinology Alzheimer Disease Risk Factors Internal medicine mental disorders medicine Humans Testosterone Risk factor Stroke Aged Aged 80 and over business.industry Cognitive disorder Odds ratio Middle Aged medicine.disease Confidence interval Cross-Sectional Studies Alzheimer's disease Cognition Disorders business |
| Zdroj: | Clinical Endocrinology. 68:589-598 |
| ISSN: | 1365-2265 0300-0664 |
| DOI: | 10.1111/j.1365-2265.2007.03094.x |
| Popis: | Summary Objective We investigated the risk of amnestic mild cognitive impairment (aMCI) in relation to serum bioavailable (BT) and total testosterone (TT) levels in older men. Design, setting and subjects A cross-sectional study in an ambulatory setting, with older men aged 55–93 years with normal cognition, aMCI and Alzheimer's disease (AD). Measurements Morning serum BT and TT levels were determined. AD was diagnosed by the Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD and aMCI by the Petersen criteria. Results We recruited 203 Chinese older men (48 aMCI, 66 AD and 89 with normal cognition). Mean serum BT, but not TT, levels were significantly lower in the aMCI (mean BT ± SEM 1·06 ± 0·10 nmol/l) and AD (0·99 ± 0·08 nmol/l) groups than in the normal controls (1·82 ± 0·12 nmol/l) (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text